Aug 10, 2026

Featuring perspectives from Dr Reva Basho, Ms Kelly Fischer, Ms Melissa Rikal and Dr Seth Wander, moderated by Dr Wander, including the following topics:

• Introduction (00:00)
• Identification of Appropriate Candidates for Agents Targeting the PI3K/AKT/mTOR Pathway (3:45)
• Role of Inavolisib in HR-Positive Metastatic...

Jul 29, 2026

Featuring perspectives from Ms Kelly Fischer, Dr Marissa Marti-Smith, Dr Rita Nanda and Dr Ruth M O'Regan, moderated by Dr Nanda, including the following topics:

• Introduction (00:00)
• Advent of CDK4/6 Inhibitors in HR-Positive Breast Cancer (BC) (1:24)
• Risk Assessment for Patients with HR-Positive,...

Jul 25, 2026

Featuring perspectives from Dr Sara A Hurvitz, Dr Erica Mayer, Dr Joyce O’Shaughnessy, Dr Sara M Tolaney and Dr Nicholas Turner, moderated by Dr Tolaney, including the following topics:

• Introduction (0:00)
• Current and Future Roles of Agents Targeting the PI3K/AKT/mTOR Pathway and Oral Selective Estrogen Receptor...

Jul 18, 2026

Featuring an interview with Prof Dr Sibylle Loibl, including the following topics:

• Perspectives on overall survival gains achieved over the years for patients with metastatic breast cancer (mBC) (0:00)
• Previous treatment and patient outcomes in the DESTINY-Breast09 trial of trastuzumab deruxtecan (T-DXd) with or...

Jul 17, 2026

Featuring a slide presentation and related discussion from Prof Dr Sibylle Loibl, including the following topics:

·      Overview of the changing landscape of treatment for patients with HER2-positive metastatic breast cancer (mBC) (0:00)

·      Results from the CLEOPATRA, PATINA and HER2CLIMB-05 trials of...